Related Experiment Videos
[2 cases of death following cell therapy]
Deutsche Medizinische Wochenschrift (1946)
|June 19, 1987
Summary
Fresh-cell therapy, unproven and unregulated, carries significant risks. Two patient deaths linked to immune reactions following fresh-cell treatments highlight the dangers of this experimental procedure.
Area of Science:
- Immunology
- Experimental Therapeutics
- Pathology
Background:
- Fresh-cell therapy lacks validation through standard clinical trials like randomized, double-blind studies.
- Parenteral administration of non-standardized heterologous antigens poses risks of severe immune reactions.
Observation:
- Two fatalities occurred in patients undergoing fresh-cell therapy.
- Case 1: A 75-year-old woman died from immune-complex vasculitis 30 days post-injection.
- Case 2: A 60-year-old woman died from perivenous leucoencephalitis 14 days after treatment.
Findings:
- Autopsy and clinical data suggest a causal link between fresh-cell therapy and patient demise.
- Fatal immune reactions, including vasculitis and leucoencephalitis, were identified as causes of death.
Implications:
- The study underscores the critical safety concerns and lack of efficacy for fresh-cell therapy.
- Highlights the potential for fatal outcomes due to unregulated antigen administration.
- Emphasizes the need for rigorous scientific validation of therapeutic interventions.